Trial designs for personalizing cancer care: A systematic review and classification

Clinical Cancer Research

Volumn 19, Issue 17, 2013, Pages 4578-4588

  Tajik, Parvin ^a   Zwinderman, Aleiko H ^a   Mol, Ben W ^a   Bossuyt, Patrick M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; PLACEBO; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER;

BAYES THEOREM; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESEARCH; CLASSIFICATION; DATA ANALYSIS; GENETIC ANALYSIS; HUMAN; INDIVIDUALIZATION; INFORMATION PROCESSING; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; METHODOLOGY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT SELECTION; PERSONALIZED MEDICINE; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESEARCH SUBJECT; REVIEW; SYSTEMATIC REVIEW;

CLINICAL TRIALS AS TOPIC; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; RESEARCH DESIGN;

EID: 84883483981     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3722     Document Type: Review

References (91)

1. Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst 2010;102:152-60.
2. Buyse M, Michiels S, Sargent DJ, Grothey A, Matheson A, de GA. Integrating biomarkers in clinical trials. Expert Rev Mol Diagn 2011;11:171-82.
3. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: one size does not fit all. J Biopharm Stat 2009;19:530-42.
4. Seymour L, Ivy SP, Sargent D, Spriggs D, Baker L, Rubinstein L, et al. The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res 2010;16:1764-9.
5. Ang MK, Tan SB, Lim WT. Phase II clinical trials in oncology: are we hitting the target? Expert Rev Anticancer Ther 2010;10:427-38.
6. Farley J, Rose PG. Trial design for evaluation of novel targeted therapies. Gynecol Oncol 2010;116:173-6.
7. McShane LM, Hunsberger S, Adjei AA. Effective incorporation of biomarkers into phase II trials. Clin Cancer Res 2009;15:1898-905.
8. Pusztai L, Hess KR. Clinical trial design for microarray predictive marker discovery and assessment. Ann Oncol 2004;15:1731-7. (Pubitemid 40012239)
9. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2- positive breast cancer. N Engl J Med 2005;353:1673-84. (Pubitemid 41464706)
10. Ziegler A, Koch A, Krockenberger K, Grosshennig A. Personalized medicine using DNA biomarkers: a review. Hum Genet 2012;131:1627-38.
11. Di MM, Gallo C, De ME, Morabito A, Piccirillo MC, Gridelli C, et al. Methodological aspects of lung cancer clinical trials in the era of targeted agents. Lung Cancer 2010;67:127-35.
12. Bria E, Di MM, Carlini P, Cuppone F, Giannarelli D, Cognetti F, et al. Targeting targeted agents: open issues for clinical trial design. J Exp Clin Cancer Res 2009;28:66.
13. Hoering A, Leblanc M, Crowley JJ. Randomized phase III clinical trial designs for targeted agents. Clin Cancer Res 2008;14:4358-67.
14. Ferraldeschi R, Attard G, de Bono JS. Novel strategies to test biological hypotheses in early drug development for advanced prostate cancer. Clin Chem 2013;59:75-84.
15. Lai TL, Lavori PW, Shih MC, Sikic BI. Clinical trial designs for testing biomarker-based personalized therapies. Clin Trials 2012;9:141-54.
16. An MW, Mandrekar SJ, Sargent DJ. A 2-stage phase II design with direct assignment option in stage II for initial marker validation. Clin Cancer Res 2012;18:4225-33.
17. Trusheim MR, Burgess B, Hu SX, Long T, Averbuch SD, Flynn AA, et al. Quantifying factors for the success of stratifiedmedicine. Nat Rev Drug Discov 2011;10:817-33.
18. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009;27:4027-34.
19. French B, Joo J, Geller NL, Kimmel SE, Rosenberg Y, Anderson JL, et al. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 2010;11:108.
20. Maitournam A, Simon R. On the efficiency of targeted clinical trials. Stat Med 2005;24:329-39. (Pubitemid 40227650)
21. Suman VJ, Dueck A, Sargent DJ. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis. Cancer Invest 2008;26:439-44. (Pubitemid 351892581)
22. Bossuyt PM, Lijmer JG, Mol BW. Randomised comparisons of medical tests: sometimes invalid, not always efficient. Lancet 2000;356:1844-7.
23. Beckman RA, Clark J, Chen C. Integrating predictive biomarkers and classifiers into oncology clinical development programmes. Nat Rev Drug Discov 2011;10:735-48.
24. Coyle VM, Johnston PG. Genomic markers for decision making: what is preventing us from using markers? Nat Rev Clin Oncol 2010;7:90-7.
25. Simon R. Development and validation of biomarker classifiers for treatment selection. J Stat Plan Inference 2008;138:308-20.
26. Paik S. Clinical trial methods to discover and validate predictive markers for treatment response in cancer. Biotechnol Annu Rev 2003;9:259-67. (Pubitemid 41085858)
27. Wang SJ, O'Neill RT, Hung HJ. Statistical considerations in evaluating pharmacogenomics-based clinical effect for confirmatory trials. Clin Trials 2010;7:525-36.
28. Lee JJ, Xuemin G, Suyu L. Bayesian adaptive randomization designs for targeted agent development. Clin Trials 2010;7:584-96.
29. Simon R. Clinical trials for predictive medicine. Stat Med 2012;31:3031-40.
30. Johnson DR, Galanis E. Incorporation of prognostic and predictive factors into glioma clinical trials. Curr Oncol Rep 2013;15:56-63.
31. Buyse M. Towards validation of statistically reliable biomarkers. Eur J Cancer Suppl 2007;5:89-95. (Pubitemid 350017011)
32. Lee CK, Lord SJ, Coates AS, Simes RJ. Molecular biomarkers to individualise treatment: assessing the evidence. Med J Aust 2009;190:631-6.
33. Simon R. Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Per Med 2010;7:33-47.
34. Le TC, Kamal M, Tredan O, Delord JP, Campone M, Goncalves A, et al. Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial. Target Oncol 2012;7:253-65.
35. Mandrekar SJ, Grothey A, Goetz MP, Sargent DJ. Clinical trial designs for prospective validation of biomarkers. Am J Pharmacogenomics 2005;5:317-25. (Pubitemid 41425609)
36. Zhou X, Liu S, Kim ES, Herbst RS, Lee JJ. Bayesian adaptive design for targeted therapy development in lung cancer-a step toward personalized medicine. Clin Trials 2008;5:181-93.
37. Sato Y, Laird NM, Yoshida T. Biostatistic tools in pharmacogenomics - advances, challenges, potential. Curr Pharm Des 2010;16:2232-40.
38. Baker SG, Kramer BS, Sargent DJ, Bonetti M. Biomarkers, subgroup evaluation, and clinical trial design. Discov Med 2012;13:187-92.
39. Mandrekar SJ, Sargent DJ. Predictive biomarker validation in practice: lessons from real trials. Clin Trials 2010;7:567-73.
40. Jiang W, Freidlin B, Simon R. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst 2007;99:1036-43. (Pubitemid 47232604)
41. Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res 2005;11:7872-8. (Pubitemid 41611633)
42. Freidlin B, Jiang W, Simon R. The cross-validated adaptive signature design. Clin Cancer Res 2010;16:691-8.
43. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521-9.
44. Freidlin B, Korn EL. Biomarker-adaptive clinical trial designs. Pharmacogenomics 2010;11:1679-82.
45. Young KY, Laird A, Zhou XH. The efficiency of clinical trial designs for predictive biomarker validation. Clin Trials 2010;7:557-66.
46. Fraser GA, Meyer RM. Biomarkers and the design of clinical trials in cancer. Biomark Med 2007;1:387-97.
47. Wang SJ. Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI. Pharm Stat 2007;6:283-96.
48. Lijmer JG, Bossuyt PM. Various randomized designs can be used to evaluate medical tests. J Clin Epidemiol 2009;62:364-73.
49. Therasse P, Carbonnelle S, Bogaerts J. Clinical trials design and treatment tailoring: general principles applied to breast cancer research. Crit Rev Oncol Hematol 2006;59:98-105. (Pubitemid 44094104)
50. Stingl Kirchheiner JC, Brockmoller J. Why, when, and how should pharmacogenetics be applied in clinical studies?: current and future approaches to study designs. Clin Pharmacol Ther 2011;89:198-209.
51. Ferrante di RL, Davenport C, Eisinga A, Hyde C, Deeks JJ. A capture-recapture analysis demonstrated that randomized controlled trials evaluating the impact of diagnostic tests on patient outcomes are rare. J Clin Epidemiol 2012;65:282-7.
52. Sargent D, Allegra C. Issues in clinical trial design for tumor marker studies. Semin Oncol 2002;29:222-30. (Pubitemid 34620439)
53. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005;23:2020-7. (Pubitemid 46211382)
54. Liu A, Liu C, Li Q, Yu KF, Yuan VW. A threshold sample-enrichment approach in a clinical trial with heterogeneous subpopulations. Clin Trials 2010;7:537-45.
55. Wang SJ, Hung HM, O'Neill RT. Adaptive patient enrichment designs in therapeutic trials. Biom J 2009;51:358-74.
56. Freidlin B, McShane LM, Polley MY, Korn EL. Randomized phase II trial designs with biomarkers. J Clin Oncol 2012;30:3304-9.
57. Song X, Pepe MS. Evaluating markers for selecting a patient's treatment. Biometrics 2004;60:874-83. (Pubitemid 40019028)
58. Bossuyt PM, McCaffery K. Additional patient outcomes and pathways in evaluations of testing. 2009 Nov 9. In: Medical tests-white paper series [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2009-. Available from: http://www.ncbi.nlm.nih.gov/books/NBK49463/.
59. Tajik P, Bossuyt PM. Genomic markers to tailor treatments: waiting or initiating? Hum Genet 2011;130:15-8.
60. Pusztai L, Anderson K, Hess KR. Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer. Clin Cancer Res 2007;13:6080-6. (Pubitemid 350075065)
61. Scheibler F, Zumbe P, Janssen I, Viebahn M, Schroer-Gunther M, Grosselfinger R, et al. Randomized controlled trials on PET: a systematic review of topics, design, and quality. J Nucl Med 2012;53:1016-25.
62. Kelloff GJ, Sigman CC. Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov 2012;11:201-14.
63. Karuri SW, Simon R. A two-stage Bayesian design for co-development of new drugs and companion diagnostics. Stat Med 2012;31:901-14.
64. Shi Q, Mandrekar SJ, Sargent DJ. Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials. Scand J Gastroenterol 2012;47:356-62.
65. Zheng G, Wu CO, Yang S, Waclawiw MA, DeMets DL, Geller NL. NHLBI clinical trials workshop: an executive summary. Stat Med 2012;31:2938-43.
66. Mandrekar SJ, Sargent DJ. All-comers versus enrichment design strategy in phase II trials. J Thorac Oncol 2011;6:658-60.
67. Mandrekar SJ, Sargent DJ. Design of clinical trials for biomarker research in oncology. Clin Investig 2011;1:1629-36.
68. Galanis E, Wu W, Sarkaria J, Chang SM, Colman H, Sargent D, et al. Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments. Curr Oncol Rep 2011;13:42-9.
69. Simon R. Clinical trials for predictive medicine: new challenges and paradigms. Clin Trials 2010;7:516-24.
70. Simon R. Advances in clinical trial designs for predictive biomarker discovery and validation. Current Breast Cancer Reports 2009;1:216-21.
71. Mandrekar SJ, Sargent DJ. Genomic advances and their impact on clinical trial design. Genome Med 2009;1:69.
72. Liu JP, Lin JR, Chow SC. Inference on treatment effects for targeted clinical trials under enrichment design. Pharm Stat 2009;8:356-70.
73. Simon R. Designs and adaptive analysis plans for pivotal clinical trials of therapeutics and companion diagnostics. Expert Opin Med Diagn 2008;2:721-9. (Pubitemid 351997859)
74. Simon R. The use of genomics in clinical trial design. Clin Cancer Res 2008;14:5984-93.
75. Ma BB, Britten CD, Siu LL. Clinical trial designs for targeted agents. Hematol Oncol Clin North Am 2002;16:1287-305. (Pubitemid 35462924)
76. European Medicines Agency. Reflection paper on methodological issues associated with pharmacogenomic biomarkers in relation to clinical development and patient selection [Internet]. London; 2011 [cited 2012 Jul 3]. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/ 2011/07/WC500108672.pdf.
77. George SL. Statistical issues in translational cancer research. Clin Cancer Res 2008;14:5954-8.
78. Van Schaeybroeck S, Allen WL, Turkington RC, Johnston PG. Implementing prognostic and predictive biomarkers in CRC clinical trials. Nat Rev Clin Oncol 2011;8:222-32.
79. Hodgson DR, Wellings R, Harbron C. Practical perspectives of personalized healthcare in oncology. N Biotechnol 2012;29:656-64.
80. Younes A, Berry DA. From drug discovery to biomarker-driven clinical trials in lymphoma. Nat Rev Clin Oncol 2012;9:643-53.
81. Buyse M, Sargent DJ, Grothey A, Matheson A, de GA. Biomarkers and surrogate end points-the challenge of statistical validation. Nat Rev Clin Oncol 2010;7:309-17.
82. Simon R, Wang SJ. Use of genomic signatures in therapeutics development in oncology and other diseases. Pharmacogenomics J 2006;6:166-73. (Pubitemid 43811567)
83. Berry DA, Herbst RS, Rubin EH. Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials. Clin Cancer Res 2012;18:638-44.
84. Scher HI, Nasso SF, Rubin EH, Simon R. Adaptive clinical trial designs for simultaneous testing ofmatched diagnostics and therapeutics. Clin Cancer Res 2011;17:6634-40.
85. Conley BA, Taube SE. Prognostic and predictive markers in cancer. Dis Markers 2004;20:35-43. (Pubitemid 39149913)
86. Wistuba II, Gelovani JG, Jacoby JJ, Davis SE, Herbst RS. Methodological and practical challenges for personalized cancer therapies. Nat Rev Clin Oncol 2011;8:135-41.
87. Cho D, McDermott D, Atkins M. Designing clinical trials for kidney cancer based on newly developed prognostic and predictive tools. Curr Urol Rep 2006;7:8-15. (Pubitemid 44624025)
88. Jones CL, Holmgren E. An adaptive Simon two-stage design for phase 2 studies of targeted therapies. Contemp Clin Trials 2007;28:654-61. (Pubitemid 47212846)
89. Spira A, Edmiston KH. Clinical trial design in the age of molecular profiling. Methods Mol Biol 2012;823:19-34.
90. White TJ, Clark AG, Broder S. Genome-based biomarkers for adverse drug effects, patient enrichment and prediction of drug response, and their incorporation into clinical trial design. Per Med 2006;3:177-85.
91. Eickhoff JC, Kim K, Beach J, Kolesar JM, Gee JR. A Bayesian adaptive design with biomarkers for targeted therapies. Clin Trials 2010;7:546-56.